Expression of BAFF-R and TACI in reactive lymphoid tissues and B-cell lymphomas

Histopathology

Volumn 54, Issue 2, 2009, Pages 221-232

  Wada, Kiriko ^a   Maeda, Kunihiko ^a   Tajima, Katsushi ^a   Kato, Takeo ^a   Kobata, Tetsuji ^b   Yamakawa, Mitsunori ^a  

^a YAMAGATA UNIVERSITY   (Japan)

^b DOKKYO MEDICAL UNIVERSITY   (Japan)

Author keywords

BAFF R; Diffuse large B cell lymphoma; Immunohistochemistry; RT PCR; TACI

Indexed keywords

B CELL ACTIVATING FACTOR; B CELL ACTIVATING FACTOR BELONGING TO THE TUMOR NECROSIS FACTOR FAMILY; B CELL ACTIVATING FACTOR RECEPTOR; COMMON ACUTE LYMPHOBLASTIC LEUKEMIA ANTIGEN; INTERFERON REGULATORY FACTOR 4; MESSENGER RNA; TRANSMEMBRANE ACTIVATOR AND CAML INTERACTOR; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGED; ARTICLE; B CELL LYMPHOMA; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; FOLLICULAR LYMPHOMA; GERMINAL CENTER; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LARGE CELL LYMPHOMA; LYMPHOID TISSUE; MAJOR CLINICAL STUDY; MALE; MANTLE CELL LYMPHOMA; MARGINAL ZONE LYMPHOMA; MULTIPLE MYELOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; B-CELL ACTIVATION FACTOR RECEPTOR; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIERS ESTIMATE; LYMPHOID TISSUE; LYMPHOMA, B-CELL; MALE; MIDDLE AGED; PROGNOSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TRANSMEMBRANE ACTIVATOR AND CAML INTERACTOR PROTEIN; TUMOR MARKERS, BIOLOGICAL;

EID: 58649102919     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/j.1365-2559.2008.03203.x     Document Type: Article

References (38)

1. Batten M, Groom J, Cachero TG et al. BAFF mediates survival peripheral immature B lymphocytes. J. Exp. Med. 2000 192 1453 1466.
2. Mackey F, Schneider P, Rennert P, Browning J. BAFF and APRIL: a tutorial on B cells survival. Annu. Rev. Immunol. 2003 21 231 264.
3. Craxton A, Magaletti D, Ryan EJ, Clark EA. Macrophage and dendritic cell dependent regulation of human B-cell proliferation requires the TNF family ligand BAFF. Blood 2003 101 4464 4471.
4. Hase H, Kanno Y, Kojima M et al. BAFF/BLyS can potentiate B-cell selection with the B-cell co-receptor complex. Blood 2003 103 2257 2265.
5. Scapini P, Nardelli B, Nadali G et al. G-CSF stimulated neutrophils are a prominent source of functional BLyS. J. Exp. Med. 2003 197 297 302.
6. Ju ZL, Shi GY, Zuo JX, Zhang JW, Jian Sun. Unexpected development of autoimmunity in BAFF-R-mutant MRL-lpr mice. Immunology 2007 120 281 289.
7. Hsu BL, Harless SM, Lindsley RC, Hilbelt DM, Cancro MP. BLyS enables survival of transitional and mature B cells through distinct mediators. J. Immunol. 2002 168 5993 5996.
8. Gross JA, Johnston J, Mudri S et al. TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease. Nature 2000 404 995 999.
9. Thompson JS, Bixler SA, Qian F et al. BAFF-R, a newly identified TNF receptor that specifically interacts with BAFF. Science 2001 293 2108 2111.
10. Bossen C, Schneider P. BAFF, APRIL and their receptors: structure, function and signaling. Semin. Immunol. 2006 18 263 275.
11. Sakurai D, Kanno Y, Hase H, Kojima H, Okumura K, Kobata T. TACI attenuates antibody production costimulated by BAFF-R and CD40. Eur. J. Immunol. 2007 37 110 118.
12. Xu S, Lam KP. B-cell maturation protein, which binds the tumor necrosis factor family members BAFF and APRIL, is dispensable for humoral immune responses. Mol. Cell. Biol. 2001 21 4067 4074.
13. O'Connor BP, Raman VS, Erickson LD et al. BCMA is essential for the survival of long-lived bone marrow plasma cells. J. Exp. Med. 2004 199 91 97.
14. Yan M, Wang H, Chan B et al. Activation and accumulation of B cells in TACI-deficient mice. Nat. Immunol. 2001 2 638 643.
15. Seshasayee D, Valdez P, Yan M, Dixit VM, Tumas D, Grewal IS. Loss of TACI causes fetal lymphoproliferation and autoimmunity, establishing TACI as an inhibitory BLyS receptor. Immunity 2003 18 279 288.
16. Ng LG, Sutherland APR, Newton R et al. B-cell activating factor belonging to the TNF family (BAFF)-R is the principal BAFF receptor facilitating BAFF costimulation of circulating T and B cells. J. Immunol. 2004 173 807 817.
17. Zhang X, Park C, Yoon S et al. BAFF supports human B cell differentiation in the lymphoid follicles through distinct receptors. Int. Immunol. 2005 17 779 788.
18. Shulga-Morskaya S, Dobles M, Walsh ME et al. B cell-activating factor belonging to the TNF family acts through separate receptors to support B cell survival and T cell-independent antibody formation. J. Immunol. 2004 173 2331 2341.
19. Sasaki Y, Casola S, Kutok JL, Rajewsky K, Schmidt-Supprian M. TNF family member B cell-activating factor (BAFF) receptor-dependent and -independent roles for BAFF in B cell physiology. J. Immunol. 2004 173 2245 2252.
20. He B, Chadburn A, Jou E, Schattner EJ, Knowles DM, Cerutti A. Lymphoma B cells evade apoptosis through the TNF family members BAFF/BLyS and APRIL. J. Immunol. 2004 172 3268 3279.
21. Kern C, Cornuel J, Billard C et al. Involvement of BAFF and APRIL in the resistance to apoptosis of B-CLL autocrine pathway. Blood 2004 103 679 688.
22. Novak AJ, Darce JR, Arendt BK et al. Expression of BCMA, TACI, and BAFF-R in multiple myeloma: a mechanism for growth and survival. Blood 2004 103 689 694.
23. Briones J, Timmerman JM, Hilbert DM, Levy R. BLyS and BLyS receptor expression in non-Hodgkin lymphoma. Exp. Hematol. 2002 30 135 141.
24. Novak AJ, Grote DM, Stenson M et al. Expression of BLyS and its receptors in B-cell non-Hodgkin lymphoma: correlation with disease activity and patient outcome. Blood 2004 104 2247 2253.
25. Nakamura N, Hase H, Sakurai D et al. Expression of BAFF-R (BR3) in normal and neoplastic lymphoid tissues characterized with a newly developed monoclonal antibody. Virchows Arch. 2005 477 53 60.
26. Rodig SJ, Shahsafaei A, Li B, Mackay CR, Dorfman DM. BAFF-R, the major B cell-activating factor receptor, is expressed on most mature B cells and B-cell lymphoproliferative disorders. Hum. Pathol. 2005 36 1113 1119.
27. Chiu A, Xu W, He B et al. Hodgkin lymphoma cells express TACI and BCMA receptors and generate survival and proliferation signals in response to BAFF and APRIL. Blood 2007 109 729 739.
28. Hans CP, Weisenburger DD, Greiner TC et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 2004 103 275 282.
29. Tsuge K, Takeda H, Kawada S, Maeda K, Yamakawa M. Characterization of dendritic cells in differentiated thyroid cancer. J. Pathol. 2005 205 565 576.
30. Hisaoka M, Tsuji S, Morimitsu Y et al. Detection of TLS/FUS-CHOP fusion transcripts in myxoid and round cell liposarcomas by nested reverse transcription-polymerase chain reaction using archival paraffin-embedded tissues. Diagn. Mol. Pathol. 1998 7 96 101.
31. Armitage JO, Weisenburger DD. New approach to classifying non-Hodgkin's lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin's lymphoma classification project. J. Clin. Oncol. 1998 16 2780 2795.
32. Alizadeh AA, Eisen MB, Davis RE et al. Distinct types of diffuse large B-lymphoma identified by gene expression profiling. Nature 2000 403 503 511.
33. Falini B, Fizzotti M, Pucciarini A et al. A monoclonal antibody (MUM1p) detects expression of the MUM1/IRF4 protein in a subset of germinal center B cells and activated T cells. Blood 2000 94 2084 2092.
34. Rolink A, Melchers F. BAFFled B cells survive and thrive: roles of BAFF in B-cell development. Curr. Opin. Immunol. 2002 14 266 275.
35. Rosenwald A, Wright G, Chan WC et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large B-cell lymphoma. N. Engl. J. Med. 2002 346 1937 1947.
36. Molina A. Decade of Rituximab: improving survival outcomes in non-Hodgkin's lymphoma. Annu. Rev. Med. 2008 59 237 250.
37. Ngo L, Hee SW, Lim LC et al. Prognostic factors in patients with diffuse large B cell lymphoma: before and after the introduction of Rituximab. Leuk. Lymphoma 2008 49 462 469.
38. Illidge T, Tolan S. Current treatment approaches for diffuse large B-cell lymphoma. Leuk. Lymphoma 2008 49 663 676.